Predictors of Days Unable to Work Among Genotype 1 Treatment-NaiVE Chronic Hepatitis C Patients: Post-Hoc Analyses of Data From Phase 3 Advance and Illuminate Studies

被引：0
|
作者：
Hernandez, Ning C.
Vera-Llonch, Montserrat
Aggarwal, Jyoti
Donepudi, Mrudula
Younossi, Zobair M.
Goss, Thomas F.
机构：
来源：
GASTROENTEROLOGY | 2012年 / 142卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S955 / S955
页数：1
相关论文
共 50 条
  • [31] Predictors of Sustained Virologic Response Among Treatment-NaiVE Patients With Hepatitis C Virus Genotype 1 When Treated With Boceprevir (Boc) Plus Peginterferon Alfa-2B-Ribavirin (PR)
    Reddy, Rajender
    Bruno, Savino
    Rossaro, Lorenzo
    Ravendhran, Natarajan
    Pauly, Mary Pat
    Boparai, Navdeep
    Sniukiene, Vilma
    Brass, Clifford A.
    Albrecht, Janice K.
    Poordad, Fred
    Jacobson, Ira M.
    GASTROENTEROLOGY, 2011, 140 (05) : S943 - S943
  • [32] Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study
    Roth, David
    Nelson, David R.
    Bruchfeld, Annette
    Liapakis, AnnMarie
    Silva, Marcelo
    Monsour, Howard, Jr.
    Martin, Paul
    Pol, Stanislas
    Londono, Maria-Carlota
    Hassanein, Tarek
    Zamor, Philippe J.
    Zuckerman, Eli
    Wan, Shuyan
    Jackson, Beth
    Nguyen, Bach-Yen
    Robertson, Michael
    Barr, Eliav
    Wahl, Janice
    Greaves, Wayne
    LANCET, 2015, 386 (10003): : 1537 - 1545
  • [33] PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 WHEN TREATED WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN (PR)
    Reddy, K. R.
    Bruno, S.
    Rossaro, L.
    Ravendhran, N.
    Pauly, M. P.
    Boparai, N.
    Sniukiene, V.
    Brass, C. A.
    Albrecht, J. K.
    Poordad, F.
    Jacobson, I. M.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S190 - S190
  • [34] Baseline predictors of null-response to peginterferon (PegIFN) α2a (40KD)/ribavirin (RBV) in treatment-naive patients with chronic hepatitis C (CHC) infected with HCV genotype 1: analysis of data from the multinational PROPHESYS cohorts
    Mangia, Alessandra
    Gervain, Judit
    Remy, Andre Jean
    Habersetzer, Francois
    Brandao-Mello, Carlos E.
    Banyai, Tivadar
    Ancuta, Ioan
    Horban, Andrzej
    Schmitz, Manuela
    Korner, Eli
    Tatsch, Fernando
    HEPATOLOGY, 2012, 56 : 588A - 589A
  • [35] Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection
    Howe, Anita Y. M.
    Black, Stuart
    Curry, Stephanie
    Ludmerer, Steven W.
    Liu, Rong
    Barnard, Richard J. O.
    Newhard, William
    Hwang, Peggy M. T.
    Nickle, David
    Gilbert, Christopher
    Caro, Luzelena
    DiNubile, Mark J.
    Mobashery, Niloufar
    CLINICAL INFECTIOUS DISEASES, 2014, 59 (12) : 1657 - 1665
  • [36] SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients
    Dieterich, Douglas
    Asselah, Tarik
    Guyader, Dominique
    Berg, Thomas
    Schuchmann, Marcus
    Mauss, Stefan
    Ratziu, Vlad
    Ferenci, Peter
    Larrey, Dominique
    Maieron, Andreas
    Stern, Jerry O.
    Ozan, Melek
    Datsenko, Yakov
    Boecher, Wulf Otto
    Steinmann, Gerhard
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (06) : 3429 - 3436
  • [37] LEDIPASVIR/SOFOSBUVIR TREATMENT FOR 8 WEEKS IN TREATMENT-NAIVE HCV GENOTYPE 1 INFECTED PATIENTS UNDER REAL LIFE CONDITIONS: DATA FROM THE GERMAN HEPATITIS C-REGISTRY (DHC-R)
    Buggisch, P.
    Boeker, K. H. W.
    Guenther, R.
    Teuber, G.
    Klinker, H.
    Pathil, A.
    Christensen, S.
    Peiffer-Vornkahl, H.
    Simon, K. -G.
    Niederau, C.
    Wedemeyer, H.
    Zeuzem, S.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S810 - S810
  • [38] SIMEPREVIR (SMV) PLUS DACLATASVIR (DCV) AND SOFOSBUVIR (SOF) IN TREATMENT-NAIVE AND -EXPERIENCED PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 OR 4 INFECTION AND DECOMPENSATED LIVER DISEASE: INTERIM RESULTS FROM THE PHASE II IMPACT STUDY
    Lawitz, E.
    Poordad, F.
    Gutierrez, J.
    Kakuda, T.
    Picchio, G.
    De La Rosa, G.
    Beets, G.
    Vandevoorde, A.
    Van Remoortere, P.
    Jacquemyn, B.
    Quinn, G.
    Luo, D.
    Ouwerkerk-Mahadevan, S.
    Vijgen, L.
    Van Eygen, V.
    Beumont, M.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S266 - S267
  • [39] Virologic response to boceprevir plus peginterferon alfa-2a (40KD) and ribavirin in treatment-naive patients with chronic hepatitis C and HCV genotype 1 infection: interim analysis of data from the international TriCo study
    Ferenci, Peter
    Flisiak, Robert
    Caruntu, Florin A.
    Lengyel, Gabriella
    Hohmann, Marc
    Tatsch, Fernando
    HEPATOLOGY, 2013, 58 : 1138A - 1139A
  • [40] Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
    Jacobson, Ira M.
    Dore, Gregory J.
    Foster, Graham R.
    Fried, Michael W.
    Radu, Monica
    Rafalsky, Vladimir V.
    Moroz, Larysa
    Craxi, Antonio
    Peeters, Monika
    Lenz, Oliver
    Ouwerkerk-Mahadevan, Sivi
    De La Rosa, Guy
    Kalmeijer, Ronald
    Scott, Jane
    Sinha, Rekha
    Beumont-Mauviel, Maria
    LANCET, 2014, 384 (9941): : 403 - 413
12345